vs
AMN HEALTHCARE SERVICES INC（AMN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是AMN HEALTHCARE SERVICES INC的1.0倍（$772.1M vs $748.2M），Revvity净利率更高（12.7% vs -1.0%，领先13.8%），Revvity同比增速更快（5.9% vs 1.8%），Revvity自由现金流更多（$161.8M vs $67.6M），过去两年Revvity的营收复合增速更高（9.0% vs -4.5%）
AMN医疗保健服务公司是美国领先的医疗人力资源解决方案提供商，主要为医院、诊所等各类医疗机构提供护士、医师、医技人员及其他临床、非临床岗位的临时与长期派遣服务，同时提供医护团队管理技术支持及相关咨询服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AMN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$748.2M
营收增速更快
RVTY
高出4.0%
1.8%
净利率更高
RVTY
高出13.8%
-1.0%
自由现金流更多
RVTY
多$94.2M
$67.6M
两年增速更快
RVTY
近两年复合增速
-4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $748.2M | $772.1M |
| 净利润 | $-7.7M | $98.4M |
| 毛利率 | 26.1% | — |
| 营业利润率 | 1.1% | 14.5% |
| 净利率 | -1.0% | 12.7% |
| 营收同比 | 1.8% | 5.9% |
| 净利润同比 | 95.9% | 3.9% |
| 每股收益（稀释后） | $-0.19 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMNRVTY
| Q4 25 | $748.2M | $772.1M | ||
| Q3 25 | $634.5M | $698.9M | ||
| Q2 25 | $658.2M | $720.3M | ||
| Q1 25 | $689.5M | $664.8M | ||
| Q4 24 | $734.7M | $729.4M | ||
| Q3 24 | $687.5M | $684.0M | ||
| Q2 24 | $740.7M | $691.7M | ||
| Q1 24 | $820.9M | $649.9M |
净利润AMNRVTY
| Q4 25 | $-7.7M | $98.4M | ||
| Q3 25 | $29.3M | $46.7M | ||
| Q2 25 | $-116.2M | $53.9M | ||
| Q1 25 | $-1.1M | $42.2M | ||
| Q4 24 | $-187.5M | $94.6M | ||
| Q3 24 | $7.0M | $94.4M | ||
| Q2 24 | $16.2M | $55.4M | ||
| Q1 24 | $17.3M | $26.0M |
毛利率AMNRVTY
| Q4 25 | 26.1% | — | ||
| Q3 25 | 29.1% | 53.6% | ||
| Q2 25 | 29.8% | 54.5% | ||
| Q1 25 | 28.7% | 56.5% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 31.0% | 56.3% | ||
| Q2 24 | 31.0% | 55.7% | ||
| Q1 24 | 31.4% | 54.6% |
营业利润率AMNRVTY
| Q4 25 | 1.1% | 14.5% | ||
| Q3 25 | 7.5% | 11.7% | ||
| Q2 25 | -18.8% | 12.6% | ||
| Q1 25 | 1.8% | 10.9% | ||
| Q4 24 | -27.6% | 16.3% | ||
| Q3 24 | 3.2% | 14.3% | ||
| Q2 24 | 5.1% | 12.4% | ||
| Q1 24 | 4.9% | 6.8% |
净利率AMNRVTY
| Q4 25 | -1.0% | 12.7% | ||
| Q3 25 | 4.6% | 6.7% | ||
| Q2 25 | -17.7% | 7.5% | ||
| Q1 25 | -0.2% | 6.4% | ||
| Q4 24 | -25.5% | 13.0% | ||
| Q3 24 | 1.0% | 13.8% | ||
| Q2 24 | 2.2% | 8.0% | ||
| Q1 24 | 2.1% | 4.0% |
每股收益（稀释后）AMNRVTY
| Q4 25 | $-0.19 | $0.86 | ||
| Q3 25 | $0.76 | $0.40 | ||
| Q2 25 | $-3.02 | $0.46 | ||
| Q1 25 | $-0.03 | $0.35 | ||
| Q4 24 | $-4.90 | $0.77 | ||
| Q3 24 | $0.18 | $0.77 | ||
| Q2 24 | $0.42 | $0.45 | ||
| Q1 24 | $0.45 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.0M | $919.9M |
| 总债务越低越好 | $767.1M | — |
| 股东权益账面价值 | $642.1M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.19× | — |
8季度趋势，按日历期对齐
现金及短期投资AMNRVTY
| Q4 25 | $34.0M | $919.9M | ||
| Q3 25 | $52.6M | $931.4M | ||
| Q2 25 | $41.5M | $991.8M | ||
| Q1 25 | $55.8M | $1.1B | ||
| Q4 24 | $10.6M | $1.2B | ||
| Q3 24 | $30.6M | $1.2B | ||
| Q2 24 | $48.0M | $2.0B | ||
| Q1 24 | $50.6M | $1.7B |
总债务AMNRVTY
| Q4 25 | $767.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AMNRVTY
| Q4 25 | $642.1M | $7.3B | ||
| Q3 25 | $644.4M | $7.4B | ||
| Q2 25 | $607.6M | $7.6B | ||
| Q1 25 | $715.1M | $7.6B | ||
| Q4 24 | $706.6M | $7.7B | ||
| Q3 24 | $890.7M | $7.9B | ||
| Q2 24 | $876.9M | $7.9B | ||
| Q1 24 | $854.2M | $7.8B |
总资产AMNRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.2B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.8B | $13.4B | ||
| Q1 24 | $2.9B | $13.4B |
负债/权益比AMNRVTY
| Q4 25 | 1.19× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $67.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 9.0% | 21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $233.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AMNRVTY
| Q4 25 | $75.6M | $182.0M | ||
| Q3 25 | $22.7M | $138.5M | ||
| Q2 25 | $78.5M | $134.3M | ||
| Q1 25 | $92.7M | $128.2M | ||
| Q4 24 | $72.8M | $174.2M | ||
| Q3 24 | $66.7M | $147.9M | ||
| Q2 24 | $99.5M | $158.6M | ||
| Q1 24 | $81.4M | $147.6M |
自由现金流AMNRVTY
| Q4 25 | $67.6M | $161.8M | ||
| Q3 25 | $14.8M | $120.0M | ||
| Q2 25 | $68.7M | $115.5M | ||
| Q1 25 | $82.7M | $112.2M | ||
| Q4 24 | $56.6M | $149.8M | ||
| Q3 24 | $47.4M | $125.6M | ||
| Q2 24 | $72.2M | $136.6M | ||
| Q1 24 | $63.2M | $129.7M |
自由现金流率AMNRVTY
| Q4 25 | 9.0% | 21.0% | ||
| Q3 25 | 2.3% | 17.2% | ||
| Q2 25 | 10.4% | 16.0% | ||
| Q1 25 | 12.0% | 16.9% | ||
| Q4 24 | 7.7% | 20.5% | ||
| Q3 24 | 6.9% | 18.4% | ||
| Q2 24 | 9.8% | 19.7% | ||
| Q1 24 | 7.7% | 20.0% |
资本支出强度AMNRVTY
| Q4 25 | 1.1% | 2.6% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 1.4% | 2.4% | ||
| Q4 24 | 2.2% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 2.2% | 2.7% |
现金转化率AMNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 0.77× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 9.54× | 1.57× | ||
| Q2 24 | 6.13× | 2.87× | ||
| Q1 24 | 4.70× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMN
| Travel Nurse Staffing | $208.3M | 28% |
| Allied Staffing | $146.9M | 20% |
| Labor Disruption Services | $124.3M | 17% |
| Technology And Workforce Solutions | $88.0M | 12% |
| Language Services | $69.9M | 9% |
| Other | $29.6M | 4% |
| International Nurse Staffing | $29.6M | 4% |
| Interim Leadership Staffing | $24.1M | 3% |
| Vendor Management Systems | $16.3M | 2% |
| Local Staffing | $8.6M | 1% |
| International Nurse Permanent Placement | $2.6M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
